Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647599 | PMC |
| http://dx.doi.org/10.1016/j.jceh.2024.102455 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer.
Cancer Chemother Pharmacol
December 2024
Department of Pharmacy, Akita University Hospital, Akita, Japan.
Purpose: The associations between first dose reduction or interruption by side effects and lenvatinib plasma trough concentration (C) after administration of a starting dose of 24 mg in 70 Japanese patients with thyroid cancer were evaluated.
Methods: Plasma samples were collected each week for 1 month and at the first incidence of side effects leading to dose reduction or interruption after beginning administration of 24 mg lenvatinib.
Results: The area under the receiver operating characteristic curve was 0.
Lenvatinib Maintenance Therapy After Complete Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: Alternative Strategy in a Resource-limited Setting.
J Clin Exp Hepatol
November 2024
Liver Transplantation Surgery, Gleneagles BGS Hospital, Bengaluru, Karnataka, India.
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study.
JHEP Rep
April 2024
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Republic of Korea.
Article Synopsis
- Nivolumab, an immune checkpoint inhibitor, was tested alongside external beam radiation therapy (EBRT) for treating hepatocellular carcinoma (HCC) with macrovascular invasion, aiming to evaluate its efficacy and safety.* -
- In a phase II trial involving 50 patients, the median progression-free survival (PFS) was 5.6 months, and overall survival was 15.2 months, with an objective response rate of 36% and a disease control rate of 74% observed.* -
- While 80% of patients experienced treatment-related side effects, mostly mild (like pruritus and rash), the combination therapy demonstrated promising results, indicating that it can be a viable option for managing this type
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Clin Lung Cancer
June 2024
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Article Synopsis
- * The artemis trial is a Phase II study testing a new chemotherapy regimen combining carboplatin, paclitaxel, lenvatinib, and pembrolizumab for patients with advanced or recurrent thymic carcinoma, involving 35 participants.
- * The main goal of the trial is to measure the objective response rate, while also assessing progression-free survival and safety of the treatment options.
Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer.
Eur Thyroid J
January 2024
M Ang, National Cancer Centre Singapore, Singapore, Singapore.
Objectives Anaplastic thyroid cancer (ATC) is an aggressive disease associated with poor outcomes and resistance to therapies. Our study aim was to evaluate the activity of a combinatorial regimen of sandwich sequencing of pembrolizumab immunotherapy and hypofractionated radiotherapy (RT). Methods In this case series, patients with ATC received hypofractionated RT (QUAD-shot) and intravenous pembrolizumab 200mg every 3-4 weeks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!